CA2841313C - Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof - Google Patents

Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof Download PDF

Info

Publication number
CA2841313C
CA2841313C CA2841313A CA2841313A CA2841313C CA 2841313 C CA2841313 C CA 2841313C CA 2841313 A CA2841313 A CA 2841313A CA 2841313 A CA2841313 A CA 2841313A CA 2841313 C CA2841313 C CA 2841313C
Authority
CA
Canada
Prior art keywords
group
independently selected
compound
groups
sugar alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2841313A
Other languages
English (en)
French (fr)
Other versions
CA2841313A1 (en
Inventor
Yumei Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellMosaic LLC
Original Assignee
CellMosaic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellMosaic LLC filed Critical CellMosaic LLC
Publication of CA2841313A1 publication Critical patent/CA2841313A1/en
Application granted granted Critical
Publication of CA2841313C publication Critical patent/CA2841313C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
    • C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Polyethers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2841313A 2011-07-19 2012-07-18 Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof Active CA2841313C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509296P 2011-07-19 2011-07-19
US61/509,296 2011-07-19
PCT/US2012/047255 WO2013012961A2 (en) 2011-07-19 2012-07-18 Novel crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof

Publications (2)

Publication Number Publication Date
CA2841313A1 CA2841313A1 (en) 2013-01-24
CA2841313C true CA2841313C (en) 2023-10-24

Family

ID=46640108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2841313A Active CA2841313C (en) 2011-07-19 2012-07-18 Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof

Country Status (7)

Country Link
US (1) US8907079B2 (https=)
EP (1) EP2734238B1 (https=)
JP (1) JP6240599B2 (https=)
CN (2) CN107043339B (https=)
AU (1) AU2012284055B2 (https=)
CA (1) CA2841313C (https=)
WO (1) WO2013012961A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511150B2 (en) 2011-07-19 2016-12-06 CellMosaic, Inc. Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
ES2859923T3 (es) * 2013-02-28 2021-10-04 Univ Tufts Compuestos de disulfuro para el suministro de agentes farmacéuticos
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
EP3154587B1 (en) 2014-06-13 2020-01-15 Tenboron OY Conjugates comprising an anti-egfr1 antibody
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
TWI648271B (zh) * 2014-09-23 2019-01-21 日商住友電木股份有限公司 二氮環丙烯化合物及由其衍生之組成物
CN104560026A (zh) * 2014-12-25 2015-04-29 温州医科大学附属第二医院 一种活体卵巢癌组织的靶向muc1的荧光探针及其制备方法
KR20180056750A (ko) * 2015-10-05 2018-05-29 신젠타 파티서페이션즈 아게 리보핵산의 생물학적 활성을 보존하는 방법
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
WO2019050977A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. REVERSIBLE LINKS AND THEIR USE
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
WO2019159779A1 (ja) * 2018-02-16 2019-08-22 日本ゼオン株式会社 ディップ成形体の製造方法
US12258334B2 (en) * 2018-05-01 2025-03-25 Cellmosaic Inc. Branched sugar alcohol-based compounds, and compositions and methods thereof
CN109142330B (zh) * 2018-07-31 2020-09-11 漯河医学高等专科学校 ZnS-CeO2-WO3-Al2O3丙酮氰醇气体传感器材料的制备方法及丙酮氰醇气体传感器
CN109776625B (zh) * 2019-03-18 2022-08-23 南京江原安迪科正电子研究发展有限公司 一种d-甘露糖的合成方法
WO2020215144A1 (en) * 2019-04-26 2020-10-29 Xlynx Materials Inc. Diazirine-based molecules and uses thereof
CN110563698A (zh) * 2019-07-25 2019-12-13 苏州昊帆生物股份有限公司 一种新型蛋白质交联剂及其制备方法
JP2023554517A (ja) * 2020-12-22 2023-12-27 エフ． ホフマン－ラ ロシュ アーゲー 試料中の目的の分析物を検出するための方法
JP7670072B2 (ja) * 2021-01-18 2025-04-30 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
US20220298399A1 (en) * 2021-03-19 2022-09-22 Facebook Technologies, Llc Synthesis and use of multi-functional diazirine adhesives for elastomer bonding
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN115043899B (zh) * 2022-05-24 2024-10-22 南开大学 双胺或胺与硫醇偶联的化合物及其制备方法和应用
CN117835778A (zh) * 2022-09-26 2024-04-05 清华大学 图案化量子点薄膜的制备方法、光电器件与电子设备
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2258892A (en) * 1938-08-25 1941-10-14 Benjamin R Harris Ethers of polyglycerols
US2520671A (en) 1946-10-24 1950-08-29 Gen Mills Inc Polyhydroxy compounds
US2520670A (en) 1946-10-24 1950-08-29 Gen Mills Inc Polyglycerols
US2532036A (en) 1946-10-24 1950-11-28 Gen Mills Inc Process of preparing polyhydric alcohols
GB723244A (en) * 1951-04-10 1955-02-02 Unilever Ltd Improvements in or relating to surface-active agents
US4172094A (en) 1976-12-03 1979-10-23 Merck & Co., Inc. Polyamine compounds
DE4124283A1 (de) 1991-07-15 1993-01-21 Degussa Umesterung von peptiden
GB9121279D0 (en) 1991-10-08 1991-11-20 Cerestar Holding Bv Process for the production of aminopolyols
FR2701949B1 (fr) 1993-02-22 1997-01-24 Picardie Jules Verne Universit Procédé de synthèse de nouveaux composés disaccharidiques, sans jonction glycosidique, produits obtenus par ce procédé et leurs applications comme médicament tensioactif ou agent chélatant.
EP0691327B1 (en) 1993-03-17 1999-07-21 Kao Corporation Amine derivative and dermatologic preparation containing the same
BR0012498A (pt) 1999-07-16 2002-04-02 Ici Ltd Composição agroquìmica, composto, e, métodos para tratar vegetação, para matar ou inibir vegetação, e para matar ou inibir pestes de plantas
DE01918975T1 (de) * 2000-03-24 2006-04-13 Biosphere Medical, Inc., Rockland Mikrokügelchen zur aktiven Embolisierung
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
EP2157429A3 (en) 2002-07-30 2011-12-28 Reverse Proteomics Research Institute Co., Ltd Method of inhibiting nonspecific interaction between molecules on solid phase support
FI20021772A7 (fi) * 2002-10-04 2004-04-05 Biotie Therapies Oyj Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi
US7538092B2 (en) * 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
CA2527665A1 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
CN1897812B (zh) 2003-12-03 2011-08-17 生物种属学股份公司 糖聚乙二醇化的粒细胞集落刺激因子
JP2007515410A (ja) 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン
EP1797192A1 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Modified proteins
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP2008526864A (ja) 2005-01-06 2008-07-24 ネオス テクノロジーズ インコーポレイテッド 糖断片を用いる糖結合
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
KR100699279B1 (ko) * 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
PL206420B1 (pl) 2006-08-03 2010-08-31 Politechnika Wroclawska Nowe pochodne disorbityloaminy i sposób ich otrzymywania
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
FR2906245A1 (fr) 2006-09-25 2008-03-28 Oreal Diamides hydroxyles agent d'hydratation de la peau
BRPI0720280A2 (pt) * 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
FR2921838A1 (fr) 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
JP2009249500A (ja) 2008-04-07 2009-10-29 Hakuto Co Ltd 重合性高分岐ポリマー及びその製造方法
EP2123304A1 (en) * 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
US20100024286A1 (en) 2008-07-31 2010-02-04 Smith Susan Jane Liquid fuel compositions
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
WO2010134476A1 (ja) 2009-05-19 2010-11-25 日産化学工業株式会社 長鎖グリシルポリオール型ゲル化剤およびゲル

Also Published As

Publication number Publication date
BR112014000324A8 (pt) 2019-01-29
BR112014000324A2 (pt) 2017-02-07
US20140206903A1 (en) 2014-07-24
EP2734238A2 (en) 2014-05-28
JP2014521319A (ja) 2014-08-28
WO2013012961A3 (en) 2013-08-01
AU2012284055B2 (en) 2017-09-07
CA2841313A1 (en) 2013-01-24
CN107043339A (zh) 2017-08-15
US8907079B2 (en) 2014-12-09
JP6240599B2 (ja) 2017-11-29
CN107043339B (zh) 2019-09-06
WO2013012961A2 (en) 2013-01-24
EP2734238B1 (en) 2020-02-19
AU2012284055A1 (en) 2014-01-30
CN104066451B (zh) 2017-04-05
CN104066451A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
CA2841313C (en) Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
US9907854B2 (en) Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
US20250250260A1 (en) Branched sugar alcohol-based compounds, and compositions and methods thereof
US11850286B2 (en) Sulfamide linker, conjugates thereof, and methods of preparation
US20230131121A1 (en) Branched discrete peg constructs
CN104530415B (zh) 一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
JP2014521319A5 (https=)
JP7042053B2 (ja) 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
AU717922B2 (en) Selectively functionalizable desdendrimers
US20250144236A1 (en) Nitrogen-branched non-linear pegylated lipid and application thereof
CA2528667C (en) Reagents for modifying biopharmaceuticals, the use and production thereof
EP2420518A1 (en) Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters
BR112014000324B1 (pt) Composto de álcool de açúcar monomérico e composto derivado de álcool de açúcar
US20100160409A1 (en) Highly Branched Reagents For Modifying Biopharmaceuticals, Their Preparation And Use
Fernandez-Megia Synthesis of multi-functional dendrimers for targeted delivery of nucleic acids
Paul Probing Receptors and Enzymes with Synthetic Small Molecules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170717

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240718

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702